Acute pancreatitis refers to an inflammation of the pancreas that comes on suddenly. The main functions of the pancreas include producing enzymes that help break down and digest food and secreting hormones like insulin and glucagon. Acute pancreatitis is often caused by gallstones or excessive alcohol use. Symptoms include abdominal pain that radiates to the back, nausea, vomiting, fever, and rapid pulse. Diagnosis involves blood tests, CT scan or MRI, and endoscopic ultrasound. Treatment focuses on pain management and treating the underlying cause. In severe cases which involve complications, patients may require hospitalization, intravenous fluids, nil per os status, and sometimes even surgery.
The acute pancreatitis market is estimated to be valued at USD 522.5 Mn in 2024 and is expected to reach USD 710.8 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.
The Acute Pancreatitis Market is primarily driven by the increasing incidences of gallbladder diseases like gallstones as well as other risk factors for pancreatitis like excessive alcohol consumption. Acute pancreatitis poses a significant health burden and its treatment costs are also rising steadily. Therefore, the need for effective medications and interventions to manage the condition is growing.
- Key players operating in the acute pancreatitis market are Takeda Pharmaceuticals, Novartis AG, Pfizer Inc., GlaxoSmithKline, and AbbVie Inc.
- Rising awareness about the disease and available treatment options present lucrative growth opportunities for market players.
- The market is witnessing increased expansion across countries by these players through new product launches and partnerships with local players.
Market Drivers
The main driver fueling the acute pancreatitis market is the growing prevalence of gallbladder diseases, especially gallstones. Gallstones are a leading cause of pancreatitis as they can sometimes travel to the pancreatic ducts and block them. This rising disease burden can be attributed to lifestyle changes, obesity, and lack of physical activity. According to the Centres for Disease Control and Prevention in the US, gallbladder disease affects around 20 million Americans annually. Increased awareness about risk factors and early diagnosis of conditions like gallstones can further propel market growth.
PEST Analysis
Political: Regulations regarding diagnostic procedures and reimbursement policies by various governments impact the market.
Economic: Growing healthcare expenditure and rise in disposable income in developing countries provide opportunities for industry players.
Social: Increasing prevalence of risk factors like obesity and alcohol consumption is leading to higher incidence of acute pancreatitis.
Technological: Advancements in imaging modalities help provide early diagnosis. Development of novel drug formulations aids improved treatment outcomes.
The acute pancreatitis market in terms of value is concentrated highly in North America and Europe. The United States dominates North America due to established healthcare infrastructure and high accessibility. In Europe, countries like Germany, United Kingdom and France account for major shares owing to advanced hospitals and availability of skilled medical professionals.
Asia Pacific is poised to be the fastest growing region for the acute pancreatitis market between 2029 to 2031. Rapid development of healthcare facilities, growing patient awareness regarding available treatment options and rising prevalence of risk factors are driving market growth in Asia Pacific countries like China, India and Japan. Improving reimbursement scenario also aids market expansion.
Get this Report in Japanese Language: 急性膵炎市場
Get this Report in Korean Language: 급성 췌장염 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
